Closure of the tipranavir trials SPRING and TICINO

Boehringer IngelheimAfter careful consideration of the feasibility of meeting the enrolment targets for the SPRING (Safety, efficacy and pharmacokinetics of tipranavir boosted with low dose ritonavir (500mg/200mg) twice daily in 400 racially and gender diverse HIV-positive treatment-experienced population) and TICINO (safety and efficacy of tipranavir/ritonavir in treatment-experienced patients also infected with the hepatitis B or hepatitis C viruses) trials, Boehringer Ingelheim has terminated both studies.

These trials have been stopped due to poor enrolment and not to any safety or efficacy reasons. Both the EMEA and the FDA are in agreement with the decision to halt these trials.

SPRING was designed to compare the safety and efficacy of tipranavir/ritonavir in a diverse treatment-experienced male and female population. TICINO was designed to compare the safety and efficacy of tipranavir/ritonavir in treatment-experienced patients also infected with the hepatitis B or hepatitis C viruses.

The success of modern HIV treatments including nevirapine has reduced the number of patients experiencing virologic failure on their earlier regimens and the duration of treatment in any line has increased. This is excellent news for those with HIV, but it also means that the original recruitment goals for the trials, 400 patients for SPRING and a further 200 patients for TICINO, was unfeasible. These 600 patients had to demonstrate previous treatment with at least three classes of HIV therapies and show resistance to more than one protease inhibitor drug. It is estimated that both trials would need to be open for more than 15 years to accrue the patient numbers required in order to have a meaningful result.

Boehringer Ingelheim remains committed to improving HIV therapy by providing physicians and patients with innovative antiretroviral treatment options for early and late treatment lines.

Aptivus® (tipranavir), a non-peptidic protease inhibitor which works by inhibiting the viral protease (an enzyme needed to complete the HIV replication process), remains a valuable option for treatment-experienced patients, helping them achieve and sustain viral undetectability even in patients resistant to multiple protease inhibitors.

Viramune® (nevirapine) is a product of original research done at Boehringer Ingelheim and was the first member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class of anti-HIV drugs on the market.

For further information, please visit:
http://www.boehringer-ingelheim.com/hiv

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

SMi Group announces the 9th Annual RNA Therapeutic…

21 - 22 February 2018, London, UK. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]